Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure - Wikidata - awgldk - TriplyDB

Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure

Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure

http://www.wikidata.org/entity/Q28306178

about

Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia Strategies to overcome antileishmanial drugs unresponsiveness A Luciferase-Expressing Leishmania braziliensis Line That Leads to Sustained Skin Lesions in BALB/c Mice and Allows Monitoring of Miltefosine Treatment Outcome Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).In vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal: genomic and metabolomic characterization.Fractal Geometry-Based Decrease in Trimethoprim-Sulfamethoxazole Concentrations in Overweight and Obese People.Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study.Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis Lack of Clinical Pharmacokinetic Studies to Optimize the Treatment of Neglected Tropical Diseases: A Systematic Review Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes.Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection.Functional Validation of ABCA3 as a Miltefosine Transporter in Human Macrophages: IMPACT ON INTRACELLULAR SURVIVAL OF LEISHMANIA (VIANNIA) PANAMENSIS.Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis.Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.Chemotherapy of leishmaniasis: present challenges.Evaluating drug resistance in visceral leishmaniasis: the challenges.Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome.Experience with miltefosine for persistent or relapsing visceral leishmaniasis in solid organ transplant recipients: A case series from Spain.Visceral leishmaniasis: a forgotten epidemic.Supervised Machine-Learning Reveals That Old and Obese People Achieve Low Dapsone Concentrations.Silver and Nitrate Oppositely Modulate Antimony Susceptibility through Aquaglyceroporin 1 in Leishmania (Viannia) Species.Drug resistance and treatment failure in leishmaniasis: A 21st century challenge.Leishmanicidal candidate LASSBio-1736, a cysteine protease inhibitor with favorable pharmacokinetics: low clearance and good distribution.Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.Leishmaniasis in humans: drug or vaccine therapy?Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study.Evidence of a drug-specific impact of experimentally selected paromomycin and miltefosine resistance on parasite fitness in Leishmania infantum.Why miltefosine-a life-saving drug for leishmaniasis-is unavailable to people who need it the most.Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives Failure of Miltefosine Treatment in Two Dogs with NaturalLeishmania infantumInfection

P2860

Q21132005-04506849-ADD6-4B8D-8749-5284D83135EE Q26849297-F2B3DFC0-AF21-477D-9EF5-BE3FB21C6649 Q27303693-F7F08B13-1A33-4B24-8FE0-9B4894A3CCB1 Q28088410-B5A51836-5FBE-4F8A-AF39-1B6EE0D3E296 Q28554069-3BBFCF84-98BC-458D-8E30-6F8A01E4E9B2 Q30275257-79882BD6-9D48-4B7A-8754-1FA7F73C3C2A Q30380900-52850DB1-2736-452A-A867-2BC3F16D8360 Q30395441-420220DB-6AB4-4902-B799-6AA263E2B92B Q33570722-57F01974-AD22-4914-9006-FB3245658D0A Q33602811-05D2E74A-F914-4349-8721-0A8BB51FB178 Q33658786-BD946E0A-9A9C-4615-8060-8AC7A722DA6A Q36001763-C32D2435-DF24-4EC0-8A37-9BF33BF29E3F Q36730131-72CB1634-AD95-44E6-A859-8378E9D66BF5 Q36850042-C7D3C722-A569-49FF-9BFF-F636CBA18DF0 Q37669845-81948790-5A5E-488E-9175-66A947D12943 Q38653256-709FC2EC-26F6-4B71-8463-DDD3DC648FCC Q39011875-AAECBB2D-358C-4F7B-8E69-C459B7CC073F Q39014583-3C749D56-6745-4133-A78D-DF6E5394C460 Q39063747-F530E1BD-0963-491B-A8D0-F218C9581626 Q39262349-F4E6E81B-5843-4498-82CF-C45B0E8A3F6B Q39632056-3A9022A3-FAF7-45EA-BF38-ED2692132533 Q40187269-14CAB2EA-FD14-4E4C-96CC-2A5CA9B50232 Q42407627-B657A041-F951-4773-B39F-F8DEF9814BE1 Q46380663-A3ED77F5-4E36-4781-88F5-4EFC0EF2329B Q47379695-686C230C-C18A-4B2E-85A1-4CACFE7D748A Q47548487-3FCA4B05-264C-41C9-9F61-D8EC443E1D77 Q47556262-3148F62E-8222-4D5C-8CB7-63FAC8BDA885 Q47898726-20484514-86A3-432E-9A2A-EBF60C77C8DD Q53120855-5051ABE8-48B1-4101-8088-CE61E251B472 Q54961274-3AA56C81-A644-405A-889E-22CA0B555C33 Q57166879-213D448E-2DAC-45F2-B550-03AAFE90B499 Q59039768-35ACEB85-36FD-4BF8-81EE-4C169AFA2C6D

P2860

Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure

http://www.wikidata.org/entity/Q28306178

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure

@ast

Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure

@en

Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure

@nl

type

label

Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure

@ast

Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure

@en

Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure

@nl

prefLabel

Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure

@ast

Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure

@en

Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure

@nl

P1433

Q28306178-3B6EFAB7-A0FC-4739-AF30-5679544158B8

P1476

Q28306178-65CCF56A-9E61-4D09-90F5-E1D5E1A6D2E3

P2093

Q28306178-0242CD6A-BC1A-418A-93FC-5372BCAC61C5

Q28306178-57FC35E5-7EAA-47B6-A12E-69E866BFE0A8

Q28306178-5BBBCF35-9902-45CF-A413-AC0E82317F61

Q28306178-5EC255C8-706C-4E11-B32E-DC05E23E11BD

Q28306178-6119DD4A-C91C-4E77-A405-E86F443B1C2F

Q28306178-98228F7A-A862-42EF-8DC1-A4A0560259BA

Q28306178-C1EA5181-754F-4ADC-BFA1-BC9C68090EC2

Q28306178-DBB8729B-F286-4A4D-8528-F5450C14A11F

Q28306178-F905FD4F-DC78-4E68-9374-64CF98796264

P2860

Q28306178-063262D0-81D6-499C-AD84-BDF44392F42F

Q28306178-0DED0DE3-80AE-4A7D-A5F3-B64DA54BB521

Q28306178-1356FDB6-31B3-46F4-89CE-9649E69E7993

Q28306178-13E5AAE4-4D4F-405B-9ED8-A35C99BD00B8

Q28306178-1A16D48A-B104-44FE-86AE-454B2E00AAD4

Q28306178-200C5874-2FE1-4964-84D9-F154F417ABF4

Q28306178-272F25D8-9A64-46FB-BDEB-972EDCC19460

Q28306178-49DB0684-0FCC-43B5-B0BF-18FCE9C33C8D

Q28306178-4B313819-0A16-4BC1-9632-55AEEB322AAD

Q28306178-4C16CA70-B614-42FA-9855-FAE0C15D55B6

P304

Q28306178-3FD8A4E2-F326-4A0F-AFB3-B8E4F1498266

P31

Q28306178-793AEB7C-2D1E-4F41-801A-0CC17E52A2DA

P3181

Q28306178-CB137EA7-CC92-40C4-A11E-0BA587852528

P356

Q28306178-7603EEB6-6C44-4B48-8FC0-B1805DF344BF

P407

Q28306178-CCBDF03B-61FF-478F-901B-CC270474F246

P433

Q28306178-7882D6D6-C3BE-4E72-89E4-2FDB9F225F6F

P478

Q28306178-F0DA2C77-56C2-4F0E-BD5C-D7D80EB4550D

P50

Q28306178-E359E4F9-3EA0-429B-AB1A-EB2DB7E0349D

Q28306178-FF6021CA-A32A-4580-B5EA-386E43E65823

P577

Q28306178-A8F28D65-3DAB-4D2C-AC84-C14E70B4700C

P5875

Q28306178-096650E0-7163-4072-B8FD-4A533087CAA4

P698

Q28306178-00A64B89-42F9-4B49-BCDB-69E7641FAAE1

P921

Q28306178-E4CEA63B-A2DF-4C41-AD1B-2389BC5A18BA

P3181

P356

P1433

The Journal of Infectious Diseases

P1476

Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure

@en

P2093

Alwin D R Huitema

http://www.w3.org/2001/XMLSchema#string

Bart Ostyn

http://www.w3.org/2001/XMLSchema#string

Jean-Claude Dujardin

http://www.w3.org/2001/XMLSchema#string

Jos H Beijnen

http://www.w3.org/2001/XMLSchema#string

Narayan Bhattarai

http://www.w3.org/2001/XMLSchema#string

Peter J de Vries

http://www.w3.org/2001/XMLSchema#string

Rupa Singh

http://www.w3.org/2001/XMLSchema#string

Suman Rijal

http://www.w3.org/2001/XMLSchema#string

Thomas P C Dorlo

http://www.w3.org/2001/XMLSchema#string

P2860

Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis

Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance

Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis

Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming.

PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy

Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis.

Visceral leishmaniasis in the Indian subcontinent: modelling epidemiology and control

Oral miltefosine for Indian visceral leishmaniasis.

Optimal dosing of miltefosine in children and adults with visceral leishmaniasis.

P304

146-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1871614

http://www.w3.org/2001/XMLSchema#string

P356

10.1093/INFDIS/JIU039

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

210

http://www.w3.org/2001/XMLSchema#string

P50

Marleen Boelaert

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259809564

http://www.w3.org/2001/XMLSchema#string

P698

24443541

http://www.w3.org/2001/XMLSchema#string

P921

visceral leishmaniasis